Hanmi Science Co Ltd
KRX:008930

Watchlist Manager
Hanmi Science Co Ltd Logo
Hanmi Science Co Ltd
KRX:008930
Watchlist
Price: 28 950 KRW -0.69%
Market Cap: 2T KRW
Have any thoughts about
Hanmi Science Co Ltd?
Write Note

Hanmi Science Co Ltd
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hanmi Science Co Ltd
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Hanmi Science Co Ltd
KRX:008930
Cash from Investing Activities
-â‚©14.8B
CAGR 3-Years
-101%
CAGR 5-Years
14%
CAGR 10-Years
12%
Yuhan Corp
KRX:000100
Cash from Investing Activities
-â‚©153.8B
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
-2%
SK Biopharmaceuticals Co Ltd
KRX:326030
Cash from Investing Activities
â‚©225.3B
CAGR 3-Years
N/A
CAGR 5-Years
42%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Cash from Investing Activities
-â‚©273.3B
CAGR 3-Years
-154%
CAGR 5-Years
-5%
CAGR 10-Years
-16%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Cash from Investing Activities
â‚©10.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-6%
C
Celltrion Pharm Inc
KOSDAQ:068760
Cash from Investing Activities
-â‚©7.8B
CAGR 3-Years
13%
CAGR 5-Years
21%
CAGR 10-Years
14%
No Stocks Found

Hanmi Science Co Ltd
Glance View

Market Cap
2T KRW
Industry
Pharmaceuticals

Hanmi Science Co Ltd, rooted in the vibrant economic landscape of South Korea, charts a compelling narrative of innovation and strategic positioning in the pharmaceutical industry. This company, established in the mid-1960s, has evolved into a pivotal player by capitalizing on its robust research and development initiatives. It operates primarily through its subsidiary, Hanmi Pharmaceutical, leveraging cutting-edge biotechnology to engineer novel drug formulations. Their core business model rests on leveraging proprietary technologies to transition new chemical entities from the lab to the market, focusing on niche therapeutic areas such as oncology, diabetes, and autoimmune diseases. By pursuing an aggressive patent strategy, Hanmi Science not only underscores its commitment to innovation but also fortifies its revenue streams by licensing these patented technologies to global pharmaceutical heavyweights. Revenue generation for Hanmi Science is intrinsically tied to its capacity to scale its biotech advances. The company's income flows primarily from licensing agreements, where its patented drug technologies are adopted by international partners, bringing in a steady stream of licensing fees and milestone payments. Additionally, Hanmi selectively engages in product distribution across multiple international markets, further diversifying its revenue base. This strategic mix of monetary inflow via direct product sales and licensing agreements allows Hanmi Science to reinvest substantial portions back into research and development, fueling a cycle of continuous innovation and market competitiveness. Through this dynamic model, Hanmi Science dexterously navigates the complexities of the pharmaceutical landscape, cementing its status as an innovator and a reliable partner in global health advancements.

Intrinsic Value
26 451.35 KRW
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Hanmi Science Co Ltd's Cash from Investing Activities?
Cash from Investing Activities
-14.8B KRW

Based on the financial report for Sep 30, 2024, Hanmi Science Co Ltd's Cash from Investing Activities amounts to -14.8B KRW.

What is Hanmi Science Co Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
12%

Over the last year, the Cash from Investing Activities growth was -226%. The average annual Cash from Investing Activities growth rates for Hanmi Science Co Ltd have been -101% over the past three years , 14% over the past five years , and 12% over the past ten years .

Back to Top